ClinicalTrials.gg

Sepsis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,418 studies for Sepsis across more than 10 countries. 543 are recruiting or about to start. 1,365 of them are mainly about Sepsis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 8 narrower conditions too, such as Shock, Septic: 3,530 studies, 742 open.

ClinicalTrials.gov finds 3,879 studies for Sepsis. How that becomes 2,418 here

This page counts the studies the registry files under Sepsis, and those it files under no condition that list Sepsisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 3,879Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,056Filed under a narrower condition, counted on its own pageShock, Septic 516 · Bacteremia 181 · Neonatal Sepsis 155 · Endotoxemia 62 · Candidemia 60 · Viremia 36 · 2 more
  3. −118List Sepsis as a condition, but the registry did not file them under itMost often written as “Sepsis Syndrome” (12), “Abdominal Sepsis” (11), and “Central Line-associated Bloodstream Infection (CLABSI)” (8). The registry filed them under other conditions only, most often Intraabdominal Infections (14) and Systemic Inflammatory Response Syndrome (13).
  4. −287Match it another way171 name it in the title, 21 in a keyword, and 95 by a synonym or other text the search reads.
  5. 2,418The count on this page107 of them list Sepsis in their own words; the registry filed them under no condition.

Status

Completed
1,216
Status unknown
390
Recruiting
319
Not yet recruiting
200
Terminated
122
Withdrawn
74

Phase

Phase 2
238
Phase 3
213
Phase 4
154
Phase 1
102
Early Phase 1
4

Where

United States
517
China
285
France
208
Germany
141
Egypt
105
United Kingdom
95

Who develops what

Add Sepsis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 7 companies, 7 with this as their studies’ main aim; 1 with a live phase 3 study; 5 primary completions in the next 12 months. Compare AstraZeneca, ImmunityBio and Bayer here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
VancomycinRecent, limited
Evidence
  • NCT05225558 · LigaChem Biosciences, Inc. · Phase 2 · background · “Vancomycin” · registered Jan 2022
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed11 study
FluconazoleEarlier only
Evidence
  • NCT04368559 · Mundipharma · Phase 3 · comparator · “Fluconazole” · registered Apr 2020
  • NCT03667690 · Merck & Co., Inc · Phase 3 · comparator · “Fluconazole” · registered Aug 2018
Pfizer59% of its industry studiesUS: off-patent, 11 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pralurbactam☆ Track1 live phase-3 study: NCT07089186Qilu Pharmaceutical Co., Ltd.

The 1 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.pralurbactam · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07089186 Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections — primary endpoint: Proportion of Participants With a Response of Overall Success(clinical response and microbiological response)[Complicated Urinary Tract Infection (cUTI)] · 80 enrolled
  • Dec 2026 est.YD0743 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2 main aimNCT07413094 Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS — primary endpoint: Number of Ventilator-Free Days · 309 enrolled
  • 11 Feb 2027 est.Berzanoflast · AstraZeneca · Phase 2 main aimNCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. — primary endpoint: Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl). · 124 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Sepsis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 6 open · Beta-lactamase inhibitors 5 open · Inhaled anesthetics 2 open · Beta blockers 1 open · Diuretics 1 open

Coming up

170studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 319 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger. 68 (21%) take children under 18. 1 (<1%) are for women only and 2 (1%) for men only; 42 (13%) take healthy volunteers.

Recruiting studies that take each age, of 319
AgeWomenMen
1050 (16%)50 (16%)
18273 (86%)273 (86%)
30276 (87%)276 (87%)
40276 (87%)275 (86%)
50278 (87%)278 (87%)
65276 (87%)276 (87%)
75270 (85%)270 (85%)
85252 (79%)251 (79%)

Across all 2,418 studies, recruiting or not: 19% stop at 75 or younger and 16% at 65; 20% take children; 1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sepsis studies take

Of 66 phase 3 interventional studies under Sepsis, half reached primary completion within 39 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo6–28 · 32 studies——
Phase 229 mo17–37 · 60 studies—30 mo16–35 · 43 studies
Phase 2/333 mo16–88 · 18 studies——
Phase 339 mo24–65 · 66 studies—42 mo24–68 · 58 studies
Phase 425 mo15–43 · 66 studies—25 mo15–45 · 65 studies
Interventional, no phase22 mo12–40 · 324 studies—23 mo12–42 · 301 studies
Observational27 mo12–56 · 545 studies16 mo6–44 · 52 studies29 mo13–58 · 493 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped2

Newly registered26

Show 21 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,418. Browse all 2,418 → or search them.